All In Biotech

Drug Trial Radar · NCT01316874

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)

Last checked: Nov 20, 2026Latest source record: Jun 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Nov 1993

Primary completion

Apr 1997

Study completion Apr 1997

Sponsor

Sponsor type
Industry
First posted
Mar 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple courses of intravesical treatment.

Conditions

  • Carcinoma in Situ
  • Bladder Cancer

Interventions

  • Valrubicin, 800 mgDrug

    Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the efficacy of AD 32 (valrubicin) in patients with CIS of the bladder who previously have been treated with BCG for CIS and in whom recurrence or failure had occurred after multiple courses of intravesical treatment.Time frame: 12 weeks

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Stacy Childs, MD

    Alabaster, Alabama

  • William Bohnert, MD

    Phoenix, Arizona

  • Scott Swanson, MD

    Scottsdale, Arizona

  • Bruce Dalkin, MD

    Tucson, Arizona

  • Donald Gleason, MD

    Tucson, Arizona

  • William Friedel, MD

    La Mesa, California

  • Stephen Auerbach, MD

    Newport Beach, California

  • William Moseley, MD

    San Diego, California

  • Standley Brosman, MD

    Santa Monica, California

  • Eugene Dula, MD

    Van Nuys, California

  • B. Thomas Brown, MD

    Daytona Beach, Florida

  • Charles Jackson, MD

    Fort Lauderdale, Florida

  • Marc Soloway, MD

    Miami, Florida

  • Charles Brendler, MD

    Chicago, Illinois

  • Patrick Guinan, MD

    Chicago, Illinois

  • Jeffrey Ignatoff, MD

    Evanston, Illinois

  • David Wood, MD

    Lexington, Kentucky

  • John Tuttle, MD

    Lexington, Kentucky

  • Dennis Venable, MD

    Shreveport, Louisiana

  • Harold Frazier, MD

    Bethasda, Maryland

  • Myron Murdock, MD

    Greenbelt, Maryland

  • John Libertino

    Burlington, Massachusetts

  • W. Lamar Weems, MD

    Jackson, Mississippi

  • Hugh Fisher, MD

    Albany, New York

  • Michael Blute, MD

    Rochester, New York

  • Michael Wolff, MD

    Burlington, North Carolina

  • Cary Robertson, MD

    Durham, North Carolina

  • Eric Klein, MD

    Cleveland, Ohio

  • Bruce Lowe, MD

    Portland, Oregon

  • Jeffrey Cohen, MD

    Pittsburgh, Pennsylvania

  • Jacques Susset, MD

    Providence, Rhode Island

  • L. Dean Knoll, MD

    Nashville, Tennessee

  • Steohen Hardeman, MD

    Austin, Texas

  • Ian Thompson, MD

    Fort San Houston, Texas

  • Seth Lemer, MD

    Houston, Texas

  • Aaron Katz, MD

    Richmond, Virginia

  • Gary Katz, MD

    Richmond, Virginia

  • Williams Ellis, MD

    Seattle, Washington

  • Richard Boxer, MD

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.